ImpediMed (IPD.AX) Stock Price
ImpediMed Price
ImpediMed (IPD.AX) Stock | ISIN AU000000IPD8. The current ImpediMed stock price is 0.01 AUD (2026). Revenue is 16.66 M AUD. Net income is -21.92 M AUD. The P/E ratio is -0.55. Market capitalization is 12.12 M AUD. ImpediMed operates in the Health sector.
Over the last 19 years ImpediMed grew revenue by 13.9% annually, reaching 12.72 M AUD. For ImpediMed, the net margin of -182.6% is up versus -246.2% a few years ago.
ImpediMed stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of ImpediMed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ImpediMed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ImpediMed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | ImpediMed Price |
|---|
ImpediMed Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
ImpediMed Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M AUD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M AUD) |
| NET INCOME (M AUD) |
| NET INCOME GROWTH (%) |
| SHARES (B) |
| DOCUMENTS |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|
| 8 | 10 | 11 | 10 | 12 | 16 | 23 | 34 |
| 60 | 25 | 10 | -9.09 | 20 | 33.33 | 43.75 | 47.83 |
| 75 | 80 | 81.82 | 90 | 83.33 | 62.5 | 43.48 | 29.41 |
| 6 | 8 | 9 | 9 | 10 | 10 | 10 | 10 |
| -20 | -19 | -20 | -19 | -23 | -21 | -16 | -3 |
| -4.76 | -5 | 5.26 | -5 | 21.05 | -8.7 | -23.81 | -81.25 |
| 1.2 | 1.68 | 1.8 | 2.02 | 2.02 | 2.02 | 2.02 | 2.02 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales ImpediMed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ImpediMed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ImpediMed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares ImpediMed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ImpediMed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
ImpediMed stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
ImpediMed Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
ImpediMed business model & stock analysis
ImpediMed SWOT Analysis
Strengths
ImpediMed Ltd possesses a unique technology that enables the non-invasive assessment of physiological conditions through bioimpedance spectroscopy. This technology has allowed the development of innovative products that have the potential to revolutionize various medical fields.
ImpediMed Ltd holds a robust intellectual property portfolio, including patents and trademarks, which provide competitive advantages and barriers to entry for potential competitors. This strengthens the company's position in the market and enhances its ability to protect its innovative technology.
ImpediMed Ltd has successfully established a strong market presence by partnering with healthcare institutions and professionals worldwide. Its products have gained recognition for their accuracy and effectiveness, contributing to the company's reputation and brand value.
Weaknesses
ImpediMed Ltd heavily relies on strategic partnerships for distribution, marketing, and sales of its products. This dependency imposes a level of vulnerability on the company, as any disruptions or termination of partnerships could adversely impact its revenue and growth prospects.
While ImpediMed Ltd has made significant progress in expanding its market presence, there is still room for improvement in terms of market penetration. The company needs to further strengthen its marketing efforts and expand its customer base to drive greater adoption of its products.
Opportunities
The increasing preference for non-invasive medical technologies presents a significant opportunity for ImpediMed Ltd. With its unique bioimpedance spectroscopy technology, the company is well-positioned to meet the rising demand for accurate and non-invasive physiological assessments across various medical disciplines.
ImpediMed Ltd has the potential to expand its product offerings into new markets beyond its current focus areas. By identifying and targeting untapped markets, the company can diversify its revenue streams and reduce its dependence on specific regions or segments, thereby enhancing its growth prospects.
Threats
ImpediMed Ltd operates in a highly competitive industry, facing competition from both established medical device companies and emerging startups. The presence of numerous competitors increases the risk of pricing pressures and the need for continuous innovation to differentiate the company's products from others in the market.
The medical device industry is subject to strict regulatory requirements, which can pose challenges for product development, approvals, and commercialization. Additionally, reimbursement policies and limitations imposed by healthcare payers may impact the adoption and utilization of ImpediMed Ltd's products, potentially hindering market growth.
ImpediMed Eulerpool Fair Value
ImpediMed historical P/E ratio, EBIT multiple, and P/S ratio
ImpediMed annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
ImpediMed shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
ImpediMed Earnings Estimates
ImpediMed Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 2/21/2024 | -0.01AUD | 5.35 MAUD | 2024 Q2 |
| 2/22/2023 | -0.01AUD | 7.21 MAUD | 2023 Q2 |
| 8/29/2022 | -0.01AUD | 6.6 MAUD | 2022 Q4 |
| 2/25/2022 | -0.01AUD | 5.43 MAUD | 2022 Q2 |
| 8/21/2019 | -0.03AUD | 3.65 MAUD | 2019 Q4 |
EESG©
Eulerpool ESG Scorecard© for the ImpediMed stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
ImpediMed shareholder structure
| % | Name |
|---|---|
8.62673% | |
5.71049% | |
2.78331% | |
1.30797% | |
1.11387% | |
0.94098% | |
0.79297% | |
0.71188% | |
0.67561% | |
0.6147% |
ImpediMed Executives and Management Board
Mr. Dennis Schlaht
Senior Vice President - R&D and Technology
Mr. Mcgregor Grant
Chief Financial & Operating Officer, Executive Director · since 2023
Dr. Parmjot Bains
Interim Chief Executive Officer, Managing Director, Executive Director · since 2024
Ms. Christine Emmanuel-Donnelly
Non-Executive Independent Chairman of the Board
Mr. Andrew Grant
Director · since 2023
Frequently asked questions about ImpediMed
The business model of ImpediMed Ltd focuses on developing and commercializing medical devices for measuring and monitoring fluid status and tissue impedance. ImpediMed specializes in bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) technologies, which are used in various medical fields such as lymphedema, heart failure, and chronic kidney disease. The company's products provide non-invasive measurements to help clinicians assess fluid status and tissue composition, aiding in the early detection and management of various medical conditions. ImpediMed's innovative devices and solutions contribute to improved patient outcomes and cost-effective healthcare interventions.
ImpediMed stock
ImpediMed Peer Group
ImpediMed Ticker
ImpediMed FIGI
All fundamentals and in-depth analysis of ImpediMed
Our stock analysis for ImpediMed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImpediMed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.